56 related articles for article (PubMed ID: 10527073)
1. Antitumor effect of vaccinia virus in glioma model.
Timiryasova TM; Li J; Chen B; Chong D; Langridge WH; Gridley DS; Fodor I
Oncol Res; 1999; 11(3):133-44. PubMed ID: 10527073
[TBL] [Abstract][Full Text] [Related]
2. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
[TBL] [Abstract][Full Text] [Related]
3. Bi-Reporter Vaccinia Virus for Tracking Viral Infections
Chiem K; Lorenzo MM; Rangel-Moreno J; Garcia-Hernandez ML; Park JG; Nogales A; Blasco R; Martínez-Sobrido L
Microbiol Spectr; 2021 Dec; 9(3):e0160121. PubMed ID: 34817228
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
Lorenzo MM; Nogales A; Chiem K; Blasco R; Martínez-Sobrido L
Microbiol Spectr; 2022 Jun; 10(3):e0027222. PubMed ID: 35583360
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of human tumor cells to homologous complement by vaccinia virus treatment.
Okada H; Wakamiya N; Okada N; Kato S
Cancer Immunol Immunother; 1987; 25(1):7-9. PubMed ID: 3594492
[TBL] [Abstract][Full Text] [Related]
9. Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.
Dymova MA; Malysheva DO; Popova VK; Dmitrienko EV; Endutkin AV; Drokov DV; Mukhanov VS; Byvakina AA; Kochneva GV; Artyushenko PV; Shchugoreva IA; Rogova AV; Tomilin FN; Kichkailo AS; Richter VA; Kuligina EV
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398600
[TBL] [Abstract][Full Text] [Related]
10. Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene.
Cao D; Song Q; Li J; Chard Dunmall LS; Jiang Y; Qin B; Wang J; Guo H; Cheng Z; Wang Z; Lemoine NR; Lu S; Wang Y
Mol Ther Oncolytics; 2022 Jun; 25():264-275. PubMed ID: 35615262
[TBL] [Abstract][Full Text] [Related]
11. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.
Hill C; Grundy M; Bau L; Wallington S; Balkaran J; Ramos V; Fisher K; Seymour L; Coussios C; Carlisle R
Mol Ther Oncolytics; 2021 Jun; 21():47-61. PubMed ID: 33869742
[TBL] [Abstract][Full Text] [Related]
12. Retroviral transfer of the p16INK4a cDNA inhibits C6 glioma formation in Wistar rats.
Strauss BE; Fontes RB; Lotfi CF; Skorupa A; Bartol I; Cipolla-Neto J; Costanzi-Strauss E
Cancer Cell Int; 2002 Apr; 2(1):2. PubMed ID: 11983028
[TBL] [Abstract][Full Text] [Related]
13. The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies.
Ling Q; Zheng B; Chen X; Ye S; Cheng Q
Hum Vaccin Immunother; 2022 Nov; 18(6):2143698. PubMed ID: 36369829
[TBL] [Abstract][Full Text] [Related]
14. Why do poxviruses still matter?
Yang Z; Gray M; Winter L
Cell Biosci; 2021 May; 11(1):96. PubMed ID: 34022954
[TBL] [Abstract][Full Text] [Related]
15. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.
Monie DD; Bhandarkar AR; Parney IF; Correia C; Sarkaria JN; Vile RG; Li H
Neurosurg Focus; 2021 Feb; 50(2):E10. PubMed ID: 33524942
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.
Chen W; Fan W; Ru G; Huang F; Lu X; Zhang X; Mou X; Wang S
Oncol Rep; 2019 Jan; 41(1):67-76. PubMed ID: 30365143
[TBL] [Abstract][Full Text] [Related]
19. Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.
Haddad D
Front Oncol; 2017; 7():96. PubMed ID: 28589082
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
